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Abstract
The downstream of kinase (DOK)-1 is involved in the protein tyrosine kinase (PTK) pathway in mast cells, but the role of
DOK-1 in the pathogenesis of asthma has not been defined. In this study, we have demonstrated a novel regulatory role of
DOK-1 in airway inflammation and physiologic responses in a murine model of asthma using lentiviral vector containing
DOK-1 cDNA or DOK-1-specific ShRNA. The OVA-induced inflammatory cells, airway hyperresponsiveness, Th2 cytokine
expression, and mucus response were significantly reduced in DOK-1 overexpressing mice compared to OVA-challenged
control mice. The transgenic introduction of DOK-1 significantly stimulated the activation and expression of STAT-4 and T-
bet, while impressively inhibiting the activation and expression of STAT-6 and GATA-3 in airway epithelial cells. On the other
hand, DOK-1 knockdown mice enhanced STAT-6 expression and its nuclear translocation compared to OVA-challenged
control mice. When viewed in combination, our studies demonstrate DOK-1 regulates allergen-induced Th2 immune
responses by selective stimulation and inhibition of STAT-4 and STAT-6 signaling pathways, respectively. These studies
provide a novel insight on the regulatory role of DOK-1 in allergen-induced Th2 inflammation and airway responses, which
has therapeutic potential for asthma and other allergic diseases.
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Introduction
Asthma is Th2-mediated inflammatory disease characterized by
airway hyperresponsiveness (AHR), and airway remodeling that
results in bronchial eosinophil accumulation [1,2]. Allergens
trigger antigen-presenting cells to interact with naı ¨ve T cells
[3,4]. These events activate Th2 cells, resulting in the over-
production of various Th2 cytokines, such as interleukin (IL)-4, IL-
5 and IL-13, which are known to have a critical role in the
differentiation in Th2 development [5,6,7]. Both clinical and
experimental allergic inflammations lead particularly to altered
blood and lung profiles of Th1 and Th2 cytokines. It has been
shown that CD4
+ Th2 cells play a pivotal role in the pathogenesis
of asthma and other allergic inflammatory diseases [5,8,9].
The balance between Th1 and Th2 cells is tuned by the cross talk
of transcription factors. One of the major transcription factors
regulating the expression of Th2 cytokine is STAT6 [10,11,12]. The
STATs have been shown to be important in the regulation of
cytokines and growth factor-inducible transcription factors in
immune response [13,14]. Recent studies using STAT6-deficient
mice demonstrated that phosphorylation of STAT6 and its nuclear
translocation are critical for the development of Th2 cell differen-
tiation and airway responses [10,11]. A significant role of STAT6 in
airway inflammation was further supported by findings in asthmatic
patients who showed increased levels of STAT6 expression in the
lung [14]. IL-4, a prototype Th2 cytokine, enhances Th2 cell
development through STAT6, which activates GATA-3 genes
[15,16]. GATA3, as a downstream transcriptional factor of STAT6,
plays a key role in Th2 cell development by promoting Th2 cytokine
expression through binding to a variety of regulatory regions of Th2
cytokines [16,17]. On the other hand, IL-12 drives Th1 cell
differentiation through activation of STAT 4 and T-box expressed
in T cells (T-bet), Th1 transcription factor, which up-regulates IFN-c
and down-regulates IL-4 and IL-5 production [12,17,18].
Downstream of tyrosine Kinase-1 (DOK-1) is a common
substrate of many protein tyrosine kinases (PTKs) [19,20,21,22].
This is a recently discovered family of adapter molecules which
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substrates-related signaling molecules, consisting of NH2-terminal
tandem of PH and PTB domains [20,23,24]. DOK-1, initially
designated as DOK or p62
dok, was first branded as a major
substrate of p210
bcr-abl. Which tyrosine phosphorylation, DOK-1
and its closet homologue DOK-2 act as adaptor proteins and
recruit multiple SH2-containing molecules such as rasGAP and
Nck [25]. Experiments with mice lacking DOK-1 or DOK-2
established an indispensable role in the negative regulation of Erk
downstream of PTKs in various hematopoietic cells [21,26].
Furthermore, the negative regulatory role of DOK-1 was validated
by the expression of small interfering RNA directed against DOK-
1, which enhanced activation of MAP kinase and subsequent
release of arachidonic acid and TNF-a [19,20,23].
Although it has been shown that DOK-1 suppresses activation
of antigen/FceRI-mediated signaling pathway in RBL2H3 mast
cells [22,27], the role of DOK-1 in the development of allergic
inflammation and airway response has not been explored. In this
study, we hypothesized that DOK-1 plays an important regulatory
role in allergen-induced lung inflammation and physiologic
responses. To address this hypothesis, we generated and
characterized mice in which lung DOK-1 is knock-downed (KD)
or over-expressed (OE) using a lentiviral transgenic system. These
studies demonstrate that DOK-1 significantly inhibits allergen-
induced pulmonary inflammation and airway responses by
selective inhibition and stimulation of STAT6 and STAT4
signaling pathways, respectively.
Results
Generation of DOK-1 KD and DOK-1 OE mice
To understand the role of DOK-1, we generated lentiviral
vector containing DOK-1- specific ShRNA and cDNA and
evaluated the in vivo efficacy after treatment on the mice.
Knockdown efficiency of 4 different DOK ShRNA in the lung
was individually evaluated, and Clone 3 was selected because it
showed the highest efficiency in silencing DOK-1 in the lung
(.95% knockdown) (Figure 1A). Conversely, DOK is highly
expressed in the lungs of mice treated with lentivirus containing
DOK-1 cDNA (Figure 1A). The local tissue expression of DOK-1
was determined by confocal evaluations after DOK-1 immuno-
staining. We detected minimum cytosolic expression of DOK-1 in
the lung epithelial cells of control mice without OVA allergen
challenge (Figure 1B). However, the expression of DOK-1 was
increased in the animals with OVA stimulation, and immunore-
action was remarkably negative for DOK-1 knockdown mice. On
the other hand, DOK-1 overexpression was clearly appreciated in
the mice treated with lentiviral transgenic construct (Figure 1B).
These data demonstrate that DOK-1 expression is localized in the
cytosol of airway epithelial cells, and its expression in the lung is
efficiently modulated by lentiviral knockdown or transgenic
approaches.
Role of DOK-1 in OVA-induced allergic inflammation,
airway responsiveness, and OVA-specific IgE production
To define the role of DOK-1 in allergic inflammation, wild-
type, DOK-1 knockdown (DOK_ShRNA) and transgenic mice
(DOK) were sensitized and challenged with OVA. OVA
sensitization and challenge significantly increased BAL inflamma-
tory cells compared to sham controls (Figure 2A). The OVA-
induced BAL inflammation was not significantly modulated in the
DOK_ShRNA mice (Figure 2A), but there were slightly increased
eosinophil peroxidase (EPO) levels compared to OVA-challenged
mice. In contrast, DOK-1 OE mice had significantly less BAL
inflammatory responses, especially in eosinophils and lymphocytes
numbers, together with EPO levels. (Figure 2A and B). To
determine the role of DOK-1 in allergen-induced physiologic
response, we evaluated airway hyperresponsiveness (AHR) after
methacholine challenge. As we expected, OVA challenge
significantly increased AHR in a dose response manner and the
DOK_ShRNA mice showed comparable levels of airway
responsiveness. In contrast, OVA-induced AHR was abolished
in the DOK-1 transgenic mice (Figure 2C). Systemic sensitization
with OVA increased the serum levels of OVA-specific IgE and
IgG2a. DOK-ShRNA mice showed comparable levels of serum
IgE (1007.36211.3 ng/ml) compared with OVA-treated control
mice (913.26176.51 ng/ml). On the other hand, the OVA-
induced IgE levels were dramatically decreased in DOK-1
transgenic mice (323.33694.25 ng/ml). Interestingly, IgG2a levels
were not significantly changed in any of these groups of mice.
Role of DOK-1 in OVA-induced tissue responses
The effects of DOK-1 in tissue inflammatory and mucus
responses were evaluated by histologic examination of lung
sections. Impressive perivascular and peribronchial inflammation
and mucus metaplasia was noted in the mice with OVA challenge.
DOK-1 knockdown mice showed comparable levels of inflamma-
tion and mucus responses compared with OVA stimulated control
mice (Figure 3A). In contrast, OVA-induced inflammatory and
mucus responses were significantly reduced in the DOK-1
transgenic mice (Figure 3A). In accordance with these histologic
changes, the inflammatory score (Figure 3B) and mucus index
(Figure 3C) showed overexpression of DOK-1 significanlty
reduced OVA-induced inflammation and mucus production
(*p,0.05).
Role of DOK-1 in T cells and cytokine expression
To understand the mechanism of DOK-1 regulation in OVA-
induced inflammation, we characterized T cell population and
measured levels of Th1 and Th2 cytokines in the BAL fluid.
Proliferative responses revealed pulmonary CD4
+ T cell popula-
tion was significantly up-regulated in DOK-1 knockdown mice
compared to OVA-challenged control mice (Figure 4A). Intracel-
lular cytokine staining of IFN-c and IL-4 on CD4
+ T cells isolated
from BAL cells further revealed that transgenic expression of
DOK-1 significantly reduced IL-4
+ CD4
+ T cells with increased
number of IFN-c producing CD4
+ T cells (Figure 4B). Although
the total number of cells was not significantly increased in the
OVA-challenged mice with shRNA silencing of DOK-1 (Table 1),
there was a significant increase in the CD4
+ cells compared to
OVA-challenged and vehicle-treated mice (Figure 4A). Interest-
ingly, these cells are not typical Th1 or Th2 cells because the
expression of IL-4 and IFN-c was not significantly changed in the
lungs from this group of mice compared to OVA challenged and
vehicle treated mice (Figure 4B). Further characterization of these
cells remains to be determined in future studies. On the other
hand, the expression levels of IL-4, IL-5, IL-13 and eotaxin were
also significantly down-regulated in DOK-1 transgenic mice
compare to OVA-challenged control mice or DOK-1 KD mice.
In contrast, the levels of IFN-c and IL-12 in this group of mice
were higher than OVA-challenged control mice or the DOK-1
KD mice (Figure 4C). These studies demonstrate that overex-
pression of DOK-1 not only suppresses allergen-induced Th2
inflammation but also stimulates IFN-c producing Th1 cells.
Role of DOK-1 on STAT-6 and STAT-4 signaling
To define the role of DOK-1 in the Th1/Th2 immune signal
pathway, we evaluated the activation or expression of STAT-6,
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analysis revealed that DOK-1 transgenic expression significantly
reduced STAT-6 activation and GATA-3 protein levels, while
stimulating STAT-4 activation and T-bet expression (Figure 5).
We further revealed that the regulatory affect of DOK-1 on
STAT-6 and STAT-4 signaling pathways are mostly independent
from each other, because similar regulation was observed both in
STAT6 and STAT4 null mice. In the absence of STAT-6, DOK-
1 OE significantly activates STAT-4 and T-bet expression
(Figure 6A). Similarly, in the absence of STAT-4, the DOK-1
inhibition of STAT-6 activation and GATA3 expression was not
significantly affected (Figure 6B). Thus, these studies indicate that
Figure 1. DOK-1 expression in the lungs after OVA sensitization and challenge. The lentiviral vectors containing DOK-1 specific ShRNA
(DOK_ShRNA) or DOK-1 cDNA (DOK) were administrated together with controls (empty vector or vector containing non-specific scrambled ShRNA)
before OVA challenge. (A) Representative western blotting demonstrating DOK-1 protein expression in the lungs of the mice. Con, non OVA
challenged; OVA, OVA-challenged with empty lentiviral vector; DOK_ShRNA, OVA-challenged with DOK_ShRNA knockdown; DOK, OVA-challenged
with DOK-1 overexpression (B) Immunofluorescent staining on the tissue sections from the lungs using Alexa Fluor 488-conjugated DOK-1 antibody
and DAPI stains.
doi:10.1371/journal.pone.0034554.g001
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and STAT4 signaling pathways, respectively, in the regulation of
allergen-induced Th2 immune responses.
Role of DOK-1 in STAT-6 and STAT-4 expression and
nuclear translocation
In non-stimulated sham control mice, we detected only minimal
levels of cytosolic expression of STAT-4 and STAT-6 in airway
epithelial cells by immunohistochemistry. However, after OVA
Figure 2. Effects of DOK-1 in OVA-induced inflammation and airway response. (A) The recovery of BAL cells 24 hr after OVA challenge.
NEU, Neutrophil; EOS, Eosinophil; LYM, Lymphocyte; MAC, Macrophages; TOT, total cell. (B) Eosinophil peroxidase (EPO) activity in BAL fluids of OVA-
sensitized and –challenged mice. (C) Airway responsiveness to aerosolized methacholine measured by non-invasive whole body plethysmography.
(D) Serum IgE and IgG2a levels detected by ELISA. The values in all the panels represent means 6 S.E.M. At least 5 mice were included in each group.
*P,0.05, ***P,0.001 vs. OVA-challenged mice.
doi:10.1371/journal.pone.0034554.g002
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and STAT-6 from cytoplasm. The STAT-6 expression and
nuclear translocation were further increased in the OVA-
challenged DOK-1 KD mice (Figure 7A). However, DOK-1 OE
mice showed significantly reduced the expression and transloca-
tion of STAT-6 into nucleus (Figure 7A). On the other hand,
DOK-1 OE mice showed significantly increased STAT-4
expression and translocation into nucleus (Figure 7B).
Discussion
Murine models of asthma have been used to understand the
pathogenesis of human asthma [28]. In this study, we demonstrate
a novel regulatory role of DOK-1 in OVA-induced allergic
inflammation and airway responses by letiviral-mediated DOK-1
knockdown and DOK-1 transgenic mice. To our knowledge, this
study is the first to provide experimental evidence demonstrating
the regulatory role of DOK-1 in allergen-induced airway
Figure 3. Effect of DOK-1 in OVA-induced tissue inflammation and mucus responses. (A) Lung sections were stained with hematoxylin
and eosin, D-PAS, alcian blue for the evaluation of inflammatory cells and airway mucus responses. 640 of original magnification. Con, non OVA
challenged; OVA, OVA-challenged with empty lentiviral vector; DOK_ShRNA, OVA-challenged with DOK_ShRNA knockdown; DOK, OVA-challenged
with DOK-1 overexpression. At least 4 mice were included in each group. (B) Inflammatory index that scored parenchymal inflammation. At least 4
mice were included in each group. *P,0.05 (C) Mucus index evaluated by morphometric analysis representing alcian blue stained mucus cells
(percentage of positive cells) in airway epithelial cells. At least 4 mice were included in each group. *P,0.05.
doi:10.1371/journal.pone.0034554.g003
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asthma.
Asthma is an inflammatory disease characterized by Th1/Th2
balance that can proceed to life-threatening airway obstruction
[29,30,31]. Th2 cytokines, IL-4, IL-5 and IL-13 produced by
Figure 4. Effect of DOK-1 on T cells and cytokine/chemokine expression. (A) FACS Histogram analysis on BAL cells from the mice after OVA
sensitization and challenge. Con, non OVA challenged; OVA, OVA-challenged with empty lentiviral vector; DOK_ShRNA, OVA-challenged with
DOK_ShRNA knockdown; DOK, OVA-challenged with DOK-1 overexpression. Each lane indicates CD4
+ T cell population stained with Cy5-anti-CD4
antibody. (B) BAL CD4(+)T cells gated with PE-conjugated CD4 were further evaluated by intracellular staining against Cy5-conjugated-IL-4 and FITC-
conjugated-IFN-c. (C) The levels of inflammatory Th1 and Th2 cytokines and a chemokine in BAL fluid were measured by ELISA at 24 hrs after the last
OVA challenge. Data represent means 6 S.E.M. Each group contains at least 7 mice. *P,0.05, ***P,0.001 vs. OVA-challenged mice.
doi:10.1371/journal.pone.0034554.g004
The Role of DOK-1 in Ova-Induced Asthma
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34554activated CD4
+ T cells, play a central role in the pathogenesis of
asthma by controlling the key process of immunoglobulin E (IgE)
production, growth of mast cells and the differentiation and
activation of mast cells and eosinophils [32,33,34]. In contrast,
Th1 cytokines such as IFN-c and IL-12, which down-regulate Th2
responses inhibit the development of allergic lung inflammation
[35,36,37]. Thus, interventions that inhibit Th2 cytokines by
enhancing Th1 cytokine production may be useful for the
treatment of allergic asthma.
Th2 cytokines play a pivotal role in the induction, and
regulation of allergic diseases by regulating IgE production,
differentiation of naı ¨ve T cells toward Th2 cells and activation
of mast cells. The critical role of STAT-6 and GATA-3 in IL-4
signaling has been demonstrated in STAT-6 deficient mice. In the
absence of STAT-6, mice did not develop Th2 responses, Ig class
switching to IgE, AHR, mucus hypersecretion and airway
eosinophilia upon allergen sensitization and airway challenges,
highlighting the essential role of this transcription factor in the
pathogenesis of allergic asthma [16,38].
DOK-1 negatively regulates Ras-Erk signaling and functions as
an intermediary adaptor protein in this pathway [39]. Recent
studies further demonstrated that DOK-1 associates with CD45 in
a tyrosine phosphorylation dependent manner and negatively
regulate JAK/STAT pathways [25]. Moreover, site-directed
mutagenesis led to the identification of tyrosine residue (Y296) in
DOK-1 as a pivotal site for CD45/DOK-1 interaction. Upon
anti-CD3/TCR stimulation, DOK-1 translocates from the
cytoplasm to the plasma membrane to serves as a downstream
effector of CD45, and negatively regulates JAK/STAT pathways
[25]. Together with DOK-2, DOK-1 also negatively regulates
lipopolysaccarid stimulated TLR-4 signaling pathways [26]. In
addition, recent studies further demonstrated that DOK-1
regulates specific immune cell function such as mast cells [22].
However, the in vivo role of DOK-1 in allergic inflammation and
airway response has not been defined.
As an animal model of asthma, the mice sensitized and
challenged with OVA developed Th2 inflammation, mucus
metaplasia and airway hyperresponsiveness, hallmarks of asthmat-
ic airways. Because we administrated the lentiviral vectors
containing ShRNA or DOK-1 cDNA before OVA challenge,
we speculated that DOK-1 modulates effector function of immune
cells or other mediators. In particular, we noted significant
changes in the STAT-6 and STAT-4 signaling molecules in airway
epithelial cells with genetic modification of DOK-1. In accord with
this finding, a number of previous studies demonstrated that
airway epithelial cells play a critical role in allergen-induced
inflammation and physiologic response [40,41]. Present studies
clearly indicate that transgenic introduction of DOK-1 signifi-
cantly down-regulates allergen-induced STAT6 expression and its
activation (phosphorylation and nuclear translocation) in airway
epithelial cells. This data suggest that DOK-1 plays an important
role in these signaling pathways in epithelial cells, as was the case
in the hematopoietic inflammatory cells. However, we could not
rule out the possibility that DOK-1 primarily affects the
inflammatory cells such as mast cells or dendritic cells that have
the capacity to drive Th2 inflammation and tissue responses. In
this regard, the specific regulatory function DOK-1 on each
immune cell needs to be further defined in future studies. The
effect of local administration of lentiviral vectors containing these
DOK-1 transgenes also remains to be determined.
Interestingly, endogenous DOK-1 expression was increased in
the mice with OVA challenge. Although it did not reach statistical
significance, knock down DOK-1 showed a trend of increase in
BAL inflammation and airway responsiveness, especially in EPO
(+) cells and airway responsiveness at 50 mg/ml methacholine
challenge, compared to vehicle-challenged mice (Figure 2). Thus,
it is reasonable to speculate that the increased expression of
endogenous DOK-1 after OVA challenge is a partially protective
response that limit exaggerated responses to OVA allergen
challenge. Because we only noted significant suppression of
allergic responses with overexpression of DOK-1, we speculate
that the level of OVA-induced endogenous DOK-1 expression was
not enough to suppress the allergic response itself. We did not see
any significant inflammatory and histologic changes in the naive
mice with DOK-1 silencing.
Table 1. Inflammatory cell counts in the lungs from mice
challenged with OVA and DOK-1 shRNA.
Total cell CD4(+) cell IL-4(+) cell IFN-c (+)c e l l
Con 217860610786 45716112 326670 237661
OVA 1210638616088 21065164750 63776419 26176213
DOK_ShRNA 1384283618549 30731063515 63606355 23396497
DOK OE 79009969963 11930466197 44666340 52956535
doi:10.1371/journal.pone.0034554.t001
Figure 5. Effect of DOK-1 on STAT-6 and STAT-4 signaling
pathways. Expression and/or activation (phosphorylation) of STAT6,
STAT4, GATA3, and T-bet transcriptional factors were evaluated by
Western blot analysis. A representative gel photo out of 6 similar
independent experiments. Con, non OVA challenged; OVA, OVA-
challenged with empty lentiviral vector; DOK_ShRNA, OVA-challenged
with DOK_ShRNA knockdown; DOK, OVA-challenged with DOK-1
overexpression.
doi:10.1371/journal.pone.0034554.g005
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modulated OVA-induced CD4 T cell recruitment to BAL and
lungs and serum IgE levels. Interestingly, the total number of cells
in the lung was not significantly increased in the OVA-challenged
mice with shRNA silencing of DOK-1, but this group of mice
showed a significant increase in CD4(+) cells compared to OVA-
challenged and vehicle-treated mice. Further FACS evaluation
indicated possible involvement of non-Th1 or Th2 cells in these
mice, because no significant changes in the expression of Th2 (IL-
4 and IL-13) or Th1 (IFN-c) cytokines in these group mice were
noted compared to OVA-challenged and vehicle treated mice.
The potential contribution of these cells into allergic response
remains to be determined in future studies. On the other hand, the
mice treated with lentiviral vectors with DOK-1 transgene
significantly increase in the number of OVA-induced Th1 cells
(IFN-c(+), IL-4(2)) and a reduction in the number of Th2 cells (IL-
4(+), IFN-c (2)). These studies suggest that DOK-1 strongly
stimulates Th1 while suppressing Th2 polarization after antigen
stimulation. The enhanced activation and expression of STAT-4
and T-bet, the exclusive transcriptional factors for Th1 differen-
tiation, by DOK-1 transgene mechanistically support T cell
differentiation by DOK-1. Although there could be a reciprocal
interaction between STATs over transcriptional cofactors such as
CBP/p300, DOK-1 regulation of STAT-4 and STAT-6 are
mostly independent of each other, because STAT-6 or GATA-3
suppression by DOK-1 were not significantly modulated in the
absence of STAT-4. The mechanism underlying selective
activation and inhibition of STAT-6 and STAT-4 will be
important in understanding the role of DOK-1, especially in
immune cell functions. Further cell –specific regulatory mecha-
nisms of DOK-1 on STAT signaling remains to be determined in
future studies.
In our current studies, we did not note compromised IgE
response in the mice treated with shRNA silencing of DOK-1, in
contrast to the results shown in Dok-1 null mice by Yamanashi et
al [21]. The expression of endogenous DOK-1 was partially
suppressed in the cells with siRNA silencing. On the other hand, in
DOK-1 null mutant mice, all the cells including immune cells lack
DOK-1 expression from the developmental stage. We speculate
that the extent of DOK-1 knock down in a variety of immune cells
in vivo could be a major reason for the difference in the immune
cell responses between these two studies. In addition, we could not
completely exclude the possibility of inherent functional deviation
of immune cells in the DOK-1 null mice affecting the overall
allergen sensitization, processing and effector function of a variety
of immune cells. Currently, it is not clear whether the impaired
IgE response seen in DOK-1 null mice after allergen challenge
resulted from the impaired function of B cells or other immune
cells related to antigen processing. To address these controversial
Figure 6. DOK-1 regulation of STAT-4, STAT-6 signaling pathways (A) Expression and/or activation of DOK-1, STAT-4, GATA-3 and
T-bet in STAT-6 knockout and (B) DOK-1, STAT-6, GATA-3 and T-bet in STAT-4 knockout mice were evaluated by Western blot
analysis. A representative gel photo out of five similar independent experiments. Con, non OVA challenged; OVA, OVA-challenged with empty
lentiviral vector; DOK_ShRNA, OVA-challenged with DOK_ShRNA knockdown; DOK, OVA-challenged with DOK-1 overexpression.
doi:10.1371/journal.pone.0034554.g006
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null mice or cells will be important in future studies.
In summary, these studies demonstrate that DOK-1 is a
negative regulator of allergen-induced Th2 inflammation, mucus
production and airway hyperresponsiveness in a murine model of
asthma. DOK-1 may regulate Th1/Th2 balance through selective
inhibition and activation of STAT-6 and STAT-4 signaling
pathways. These studies also highlight a therapeutic potential of
DOK-1 in the intervention of asthma and other allergic diseases.
Figure 7. Effects of DOK-1 on STAT-6 and STAT-4 expression and nuclear translocation in airway epithelial cells. (A) Lung sections
were stained with Alexa Fluor 488-conjugated DOK-1 and Alexa Fluor 568-conjugated STAT-6 antibodies and DAPI stain. (B) Lung sections were
stained with Alexa Fluor 488-conjugated DOK-1 and Alexa Fluor 568-conjugated STAT-4 antibodies and DAPI stains. A representative photo of 7
similar experiments. Con, non OVA challenged; OVA, OVA-challenged with empty lentiviral vector; DOK_ShRNA, OVA-challenged with DOK_ShRNA
knockdown; DOK, OVA-challenged with DOK-1 overexpression.
doi:10.1371/journal.pone.0034554.g007
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Mice and experimental protocol
Female C57/BL6 mice, 6–8 weeks of age and free of murine-
specific pathogens, were obtained from the Orient (Seoul, Korea),
and all experimental animals used in this study were under a
protocol approved by the Institutional Animal Care and Use
Committee of the Pusan National University (PNU-2009-0036).
Mice were sensitized on days 1 and 15 by intraperitoneal injection
of 20 mg ovalbumin (OVA) (Sigma-Aldrich, St. Louis, MO) added
in 1 mg of aluminum hydroxide (Pierce Chemical Co., Rockford,
IL) in a total volume of 200 ml. One week later, mice were exposed
to aerosolized OVA once a day for 3 days. [42] Lentiviral vectors
containing DOK-1 specific ShRNA or DOK-1 cDNA were
intraperitoneally injected on days 18 and 19. The mice were
sacrificed and evaluated 24 hrs after the last OVA challenge.
(Figure S1)
Construction of lentiviral vector containing DOK-1 ShRNA
and cDNA
Four ShRNAs target sequences (Clone 1: TCRN0000088814,
clone 2: TCRN0000088815, clone 3: TCRN0000088816, clone4:
TCRN0000088817) were selected for DOK-1 knockdown exper-
iments (Mission ShRNA, Sigma-Aldrich, St. Louis, MO). DOK-1
cDNA was cloned by PCR amplification using the following
primers : 59-CTACCTGAGCTACCAGTCCGC-39 (Sense) and
59-CGTGAAGAATGTGCGAGAC-39 (antisense) (Genecopoeia,
Germantown, MD). DOK-1 ShRNAs and cDNA were further
cloned into pLKO.1-puro and transferred to 293FT cells using
calcium phosphate-mediated transfection. Then the viruses were
collected and concentrated 100-fold by ultra-centrifugation. The
virus stocks were titrated using 293FT cell-based GFP expression
assay and a viral titer of 1610
6 IFU was used in this study.
Evaluation of BAL cells
The total cell numbers were counted with a hemocytometer.
Smears of BAL cells prepared with Cytospin II (Shandon,
Runcorn, UK) were stained with Diff-Quik solution (Dade
Diagnostics of P.R. Inc, Aguada, PR) for differential cell counting.
Two independent, blinded investigators counted the cells, using a
microscope. Approximately 200 cells were counted in each of four
different random locations.
Th1 and Th2 cell evaluation
BAL cells were first blocked with 10% (v/v) normal goat serum
for 15 min at 4uC and stained with Cy5PE-conjugated mouse
mAbs against CD4, then cells were analysed on a FACSCalibur
cytometer (Becton Dickinson, Franklin Lakes, NJ). For intracellu-
lar cytokine staining, the cells were treated with brefeldin A (10 lg/
ml; 4 hr), washed with 1% v/v FBS-PBS (staining buffer), stained
with PE-conjugated mouse mAbs against CD4, IFN-g with FITC-
conjugated and IL-4 with Cy5PE-conjugated and fixed in 4% w/v
paraformaldehyde (20 min at room temperature).
Measurement of eosinophil peroxidase
The suspension of BAL cells and the pulmonary homogenates
were frozen/thawed three times using liquid nitrogen and a water
bath at 37uC to obtain the EPO. The BAL fluid was centrifuged to
4uC for 10 min and serially diluted in a 96-well plate (75 ml/well)
followed by the addition of 150 ml of substrate (1.5 mM o-
phenylenediamine and 6.6 mM H2O2 in 0.05 M Tris-HCl,
pH 8.0). After 30 min at room temperature, the reaction was
stopped by the addition of 75 ml of 30% H2SO4, and the
absorbance of the samples was determined at 492 nm on an
ELISA reader.
Histopathology
At 24 hrs after the last challenge, lungs were removed from the
mice after they had been sacrified. Prior to the removal of the
lungs, the lungs and trachea were filled intratracheally with a
fixative (4% paraformaldehyde) using a ligature around the
trachea. Lung tissues were fixed with 10% (v/v) paraformalde-
hyde. The specimens were dehydrated and embedded in paraffin.
For histological examination, 4 mm sections of fixed embedded
tissues were cut on a Leica model 2165 rotary microtome (Leica,
Nussloch, Germany), placed on glass slides, deparaffinized, and
sequentially stained with hematoxylin 2 and eosin-Y (Richard-
Allan Scientific, Kalamazoo, MI), D-PAS and Alcian Blue staing
kit (Merck, Washington, NJ). The tissue inflammation was scored
in a blinded manner as shown previously [43]. The lung sections
were taken from the same lobe in each mouse and at least 3
random sections per mouse were analyzed. A inflammation score
of 0 to 4 was assigned to each section. (0: no inflammation; 1: mild;
2: moderate; 3: severe but not in all airways; 4: severe in all
airways). Airway mucus levels were quantitated by mucus index by
counting mucus containing airway cells as a percentage of total
cells [44].
Measurement of Th1/Th2 cytokines and OVA-specific IgE,
IgG2a levels
Levels of IL-4 and IL-5 were quantified in the supernatants of
BAL fluids by enzyme immunoassays performed according to the
protocol of the manufacturer (IL-4, IL-5, IL-12, IFN-c; Eotaxin
R&D Systems, Inc., Minneapolis, MN). The levels of OVA-
specific IgE and IgG2a in serum were assessed by enzyme
immunoassays according to the manufacturer’s protocol (R&D
Systems; Minneapolis, MN).
Whole body plethysmography
Airway responsiveness was measured in mice 24 hrs after the
last challenge in an unrestrained conscious state, as described
previously [15,16]. Mice were placed in a barometric plethysmo-
graphic chamber (All Medicus Co., Seoul, Korea) and baseline
readings were taken and averaged for 3 min. Aerosolized
methacholine in increasing concentrations (2.5 to 50 mg/ml)
was nebulized through an inlet of the main chamber for 3 min.
Readings were taken and averaged for 3 min after each
nebulization. Enhanced pause (Penh), calculated as (expiratory
time/relaxation time-1)6(peak expiratory flow/peak inspiratory
flow), according to protocol of the manufacturers, is a dimension-
less value that represents a function of the proportion of maximal
expiratory to maximal inspiratory box pressure signals and a
function of the timing of expiration. Penh was used as a measure of
airway responsiveness to methacholine. Results were expressed as
the percent increase of Penh following challenge with each
concentration of methacholine, where the baseline Penh (after
saline challenge) was expressed as 100%. Penh values were
averaged for 3 min after each nebulization and evaluated.
Western blot analysis
The lung tissues were homogenized, washed with PBS, and
incubated in lysis buffer plus a protease inhibitor cocktail (Sigma,
St Louis, Mo) to obtain extracts of lung proteins. The samples
were loaded to 10% SDS-PAGE gels and were separated at 120 V
for 90 minutes. The blots were incubated with an anti-STAT-6,
STAT-4, GATA-3, T-bet antibody diluted at a ratio of 1:1000,
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The membranes were stripped and reblotted with a-tubulin
antibody (Sigma) to verify the equal loading of protein in each
lane.
Detection of STAT-6 and STAT-4 by confocal microscopy
To prepare specimens for confocal microscopy, lungs were
sectioned on 4-chamber Lab-Tek II slides (Thermo Fisher
Scientific). One day later, slides were washed twice with PBS
then blocked with 1% BSA in PBS for 20 minutes at room
temperature. Slides were stained with 0.5 mg Alexa Fluor 488-
conjugated DOK-1 and Alexa Fluor 568–labeled STAT-6 or
STAT-4 in 200 ml volume for 30 minutes, washed 5 times, then
fixed in 4% formaldehyde. Specimens were washed, excess
moisture was removed, and slides were cover-slipped using
Prolong Gold with DAPI (Invitrogen). After curing overnight,
slides were sealed with acrylic nail polish. Slides were imaged using
an Olympus Fluoview FV300 laser scanning confocal microscope.
Exposure times for individual filter sets and gain multiplication
settings were established for each experiment using unstained
specimens to determine maximal settings.
Statisitcal Evaluation
Experiments were repeated at least three times with consistent
results. Unless otherwise stated, data are expressed as the mean 6
S.E.M. ANOVA was used to compare experimental groups to
control values, while comparisons between multiple groups were
performed using Tukey’s Multiple Comparison test. Statistical
significance was indicated by a P value less than 0.05.P
***,0.001,
P
**,0.01, P
*,0.05.
Supporting Information
Figure S1 Schematic diagram of the experimental
protocol. Mice were sensitized on days 1 and 15 by
intraperitoneal injection OVA added in 1 mg of aluminum
hydroxide. After 1 week, mice were exposed to aerosolized
OVA once a day for 3 days. Lentiviral vectors containing DOK-1
specific ShRNA or DOK-1 cDNA were intraperitoneally injected
on days 18 and 19.
(TIF)
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